1. Home
  2. SUPX vs SABS Comparison

SUPX vs SABS Comparison

Compare SUPX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super X AI Technology Limited Ordinary Shares

SUPX

Super X AI Technology Limited Ordinary Shares

N/A

Current Price

$8.17

Market Cap

307.0M

Sector

N/A

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.42

Market Cap

344.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUPX
SABS
Founded
2021
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
307.0M
344.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SUPX
SABS
Price
$8.17
$3.42
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
548.6K
252.7K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
78.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.61
$1.85
52 Week High
$76.00
$5.15

Technical Indicators

Market Signals
Indicator
SUPX
SABS
Relative Strength Index (RSI) 48.63 35.73
Support Level $6.75 $3.38
Resistance Level $11.65 $4.02
Average True Range (ATR) 1.33 0.13
MACD -0.18 -0.04
Stochastic Oscillator 24.95 3.45

Price Performance

Historical Comparison
SUPX
SABS

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: